Lifecore Biomedical, Inc. (LFCR)

Lifecore Biomedical's shares plunged over 33% following its Q4 2025 earnings report due to management's update on delayed volume expectations from its largest customers in March 2026. Barrington Research upgraded Lifecore Biomedical in March 2026. Lifecore Biomedical announced its inclusion in the Nasdaq Biotech Index, effective December 22, 2025. The company reported strong financial outcomes for the three months ended September 30, 2025, with a 26% increase in revenue compared to the prior year comparable period and significant improvements in SG&A expense and affirmed its guidance for the calendar year 2025 transition period in November 2025. Lifecore Biomedical signed an agreement with a leading global pharmaceutical company for commercial manufacturing transfer of an injectable pharmaceutical product and a separate agreement with an early-stage biotechnology company for pre-clinical formulation development services in October 2025. Lifecore announced it would be moving its fiscal year end to align with the calendar year, effective for the December 31, 2025, calendar period, reported $128.9 million in fiscal 2025 revenue, meeting full-year guidance, and signed nine new programs with new customers in August 2025.

Lifecore Biomedical is generally not significantly affected by seasonality. However, the timing of customer orders and the scale, scope, mix, and duration of fulfilling these orders can lead to variability in the company's revenues. The company's decision to move its fiscal year end to align with the calendar year, effective December 31, 2025, was partly to move away from a fiscal year end based on legacy businesses' seasonality and to align with industry peers.

Lifecore Biomedical, Inc. (LFCR) is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, cGMP manufacturing, and aseptic filling of complex formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges. The company operates within the Pharmaceuticals & Biotech sector, specifically in the Life Sciences Tools and Services industry, and is also categorized under Drug Manufacturers - Specialty & Generic. Lifecore Biomedical is a leading manufacturer of premium, injectable-grade hyaluronic acid (HA) in bulk form, which is a naturally occurring polysaccharide used in formulated and filled syringes and vials for injectable products across various medical conditions and procedures. The company also offers capabilities for non-HA devices and drug opportunities.

Lifecore Biomedical, Inc. is headquartered in Chaska, Minnesota, United States. Its campus, located in the Twin Cities area, includes facilities for aseptic formulation and filling, secondary packaging, microbiology and analytical quality control labs, sodium hyaluronate manufacturing (fermentation), and warehousing. The company serves global and emerging biopharmaceutical and biotechnology companies.

In the past year, Lifecore Biomedical has demonstrated a growing reputation for technical excellence, quality, and reliability in sterile injectables, as evidenced by signing new commercial manufacturing agreements with leading global pharmaceutical companies. The company's long-standing track record of over 40 years with global regulatory bodies like the FDA, EMA, and ANVISA also contributes to its strong reputation for cGMP compliance and manufacturing excellence. In March 2025, the FDA completed a general drug product good manufacturing practices inspection of Lifecore, which was closed in May 2025 without further required action, further affirming its quality standards. The company's strategic shift to become a pure-play CDMO and its investments in expanding aseptic production capabilities have also been viewed positively.

Lifecore Biomedical, Inc. has a mixed ownership structure comprising institutional, retail, and individual investors. Institutional investors collectively hold a substantial stake, with figures ranging from approximately 51.94% to 83.36% of the company's stock. Major institutional shareholders include Wynnefield Capital Inc., Legion Partners Asset Management, LLC, Greenhaven Road Investment Management, L.P., BlackRock, Inc., Vanguard Group Inc., 325 Capital Llc, Geode Capital Management, Llc, Morgan Stanley, Grizzlyrock Capital, Llc, and State Street Corp. Individual investors held approximately 35% as of November 2024. Insiders' holdings were around 3.47% in January 2025 and 4.52% as of July 2025.